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ABSTRACT 29 
This study investigates GABAB protein expression and mRNA levels in three types of 30 
specimens. Two types of specimens from patients with temporal lobe epilepsy (TLE), 31 
secondary to hippocampal sclerosis, sclerotic hippocampal samples (TLE-HS), and tissue 32 
from the structurally preserved healthy, non-spiking ipsilateral superior temporal gyrus 33 
(TLE-STG) removed from the same patient during epilepsy surgery; and third specimen is 34 
hippocampal tissue specimen from individuals with no history of epilepsy (post-mortem 35 
controls, PMC).  36 
mRNA expression of GABAB subunits was quantified in TLE-HS, TLE-STG and PMC 37 
specimens by qRT-PCR. Qualitative and quantitative Western blot (WB) and 38 
immunohistochemistry techniques were employed to quantify and localize GABAB 39 
proteins subunits. 40 
qRT-PCR data demonstrated an overall decrease of both GABAB1 isoforms in TLE-HS 41 
compared to TLE-STG. These results were mirrored by the WB findings. GABAB2 mRNA 42 
and protein were significantly reduced in TLE-HS samples compared to TLE-STG; 43 
however they appeared to be upregulated in TLE-HS compared to the PMC samples. 44 
Immunohistochemistry (IHC) showed that GABAB proteins were widely distributed in PMC 45 
and TLE-HS hippocampal sections with regional differences in the intensity of the signal.  46 
The higher expression of mature GABAB protein in TLE-HS than PMC is in agreement 47 
with previous studies. However, these findings could be due to post-mortem changes in 48 
PMC specimens. The TLE-STG samples examined here represent a better ‘control’ tissue 49 
compared to TLE-HS samples characterized by lower than expected GABAB expression. 50 
This interpretation provides a better explanation for previous functional studies suggesting 51 
reduced inhibition in TLE-HS tissue due to attenuated GABAB currents.  52 
 53 
KEYWORDS: human temporal lobe epilepsy, hippocampal sclerosis, GABAB qRT-PCR, 54 
quantitative Western blot, immunohistochemistry. 55 
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1. INTRODUCTION 57 
The main inhibitory neurotransmitter in the mammalian central nervous system (CNS), γ-58 
aminobutyric acid (GABA), plays important roles in regulating neuronal activity, plasticity, 59 
and pathophysiology. Its action is mediated through distinct receptor types: ionotropic 60 
(GABAA and GABAC) and metabotropic (GABAB). Both GABAA and GABAB receptors have 61 
been implicated in many important physiological functions and pathological conditions in 62 
the brain (Gassmannn and Bettler 2012, Castelli and Gessa, 2016), such as absence 63 
seizures (Stewart et al. 2009) 64 
GABAB receptors have been demonstrated at both pre- and postsynaptic sites of both 65 
excitatory and inhibitory neurones (Chen et al. 2004). Presynaptic receptor stimulation 66 
reduces the evoked release of GABA and other neurotransmitters, whereas postsynaptic 67 
GABAB receptor activation increases neuronal K+ conductance to generate long-lasting 68 
inhibitory postsynaptic potentials (IPSPs). 69 
Along with other findings, previous pharmacological and physiological studies have 70 
suggested the existence of two distinct GABAB1 receptor subtypes at pre- and 71 
postsynaptic sites and in different cells types and brain structures (Bowery 1997; Deisz et 72 
al.1997; Dutar and Nicoll 1988; Pitler and Alger 1994). The evidence for two different 73 
GABAB1 receptor isoforms (GABAB1a and GABAB1b) was first characterised by Kaupmann 74 
and colleagues (1997). A second subunit was subsequently characterised (Kaupmann et 75 
al. 1998; Jones et al. 1998; White et al. 1998).  76 
 The distribution of GABAB1 receptors in human hippocampus has been demonstrated 77 
with receptor binding autoradiography (Princivalle et al. 2002). Expression of GABAB1 78 
mRNA in the rat CNS, human hippocampus and spinal cord has been established by 79 
radiolabelled riboprobes recognising the two GABAB1 mRNA variants (Kaupmann et al. 80 
1997; Benke et al. 1999; Liang et al. 2000; Towers, et al. 2000). The expression of 81 
GABAB2 messengers has also been described widely expressed in rat brain (Clark et al. 82 
2000; Calver et al. 2000). In addition GABAB1 (a/b) and GABAB2 immunoreactivity has 83 
been demonstrated in the rat CNS (Ige et al. 2000; Princivalle et al. 2000a; 2000b; 2001; 84 
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Charles et al. 2001). Nevertheless, it is still unclear how the two GABAB1 variants and the 85 
GABAB2 mature proteins are distributed in different neuronal regions and cell types in 86 
human brain tissue such as the hippocampus, or how the transcription of GABAB1 and 87 
GABAB2 may be affected by pathological states such as epilepsy. 88 
Temporal lobe epilepsy (TLE) is the commonest and most researched drug-refractory 89 
focal epilepsy. Electrophysiological evidence has demonstrated that there is a lack of 90 
inhibition in TLE due to the abolished slow component of GABAB receptor-mediated 91 
IPSPs (Mangan and Lothman, 1996, Teichgrӓber et al. 2009). In addition, there is 92 
pharmacological and physiological evidence that GABAB receptor is impaired in animal 93 
models of TLE (Chandler et al. 2003; Furtinger et al. 2003a; Mares and Kubová 2015; 94 
Leung et al. 2016). However, the localization and quantitative expression of GABAB 95 
isoforms and subunits have not yet been elucidated in animal models or in human TLE. 96 
Previous studies reported impaired GABAB receptor mediated currents in TLE (Straessle 97 
et al. 2003; Rocha et al. 2015). This study aimed to examine possible differences in 98 
GABAB1a, GABAB1b and GABAB2 mRNA and protein expression. We investigated whether 99 
GABAB protein expression showed a reduction in the hippocampal tissue of patients with 100 
mesial temporal sclerosis (TLE-HS) compared to tissue taken from the same patients’ 101 
superior temporal gyrus (TLE-STG) and post-mortem hippocampal control (PMC) tissue 102 
from individuals with no history of epilepsy.  103 
 104 
2. MATERIALS AND METHODS 105 
2.1. Patient tissue collection and clinical data  106 
The majority of surgical samples were obtained from the Royal Hallamshire Hospital 107 
(R&D approval STH15210). The post-mortem immunohistochemistry samples were 108 
obtained from The National Hospital for Neurology and Neurosurgery.  All samples were 109 
obtained with the understanding and the written consent of each patient. The sample 110 
collection procedure fully conformed with the Code of Ethics of the World Medical 111 
Association (Declaration of Helsinki), British Medical Journal (1964), and the Institute of 112 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
 
5 
 
Neurology Joint Research Ethics Committee [Ethics Committee Protocol Pro-Forma 113 
(January 1998)]. The study was approved by the South Yorkshire Research Ethics 114 
Committee (08/H1310/49).  115 
The surgical sclerotic human hippocampal tissue (TLE-HS) and non-sclerotic (TLE-STG) 116 
samples were obtained from the same patient with medically refractory TLE, undergoing 117 
surgical resection. Only patients with TLE secondary to unilateral hippocampal sclerosis 118 
were included. Clinical and demographic information about these patients is in Table 1.  119 
The excision of the samples was based on pre-surgical clinical evaluation including 120 
interictal and ictal EEG studies and magnetic resonance imaging (MRI) in all cases. Each 121 
sample was divided into two parts, one part was snap frozen (Kingsbury et al. 1996) and 122 
stored at -80°C until RNA and protein extraction were performed. All pre-operative 123 
diagnoses of HS were confirmed after surgery by histopathological examination based on 124 
established diagnostic criteria (Thom at al. 2002),. The second part of the sample was 125 
fixed as previously described (Thom at al. 2002): briefly they were post-fixed in 4% 126 
paraformaldehyde, then dehydrated through ethanol at increasing concentration, paraffin-127 
embedded overnight, sliced by vibratome at 10 µm, mounted on slides, dried and stored 128 
at R.T. until use for histopathological analysis and immunohistochemistry experiments. 129 
The TLE-STG specimens were taken from the superior temporal gyri which looked 130 
structurally preserved on MRI, and had not been shown to generate ictal or inter-ictal 131 
epileptiform activity during pre-surgical electroencephalographic monitoring. If this kind of 132 
samples does not follow the above criteria they were not collected.  133 
The flash-frozen post-mortem hippocampal samples were obtained from the UCL Brain 134 
Bank (08/H0718/54). They were from individuals with no previous medical history of 135 
neurological or psychiatric disease (Table 2). At autopsy the hippocampi were dissected, 136 
pH was checked to be between 6 and 7, and the samples were flash frozen and stored at 137 
-80°C. 138 
 139 
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 140 
2.2. Quantitative real-time polymerase chain reaction (qRT-PCR) 141 
2.2.1. RNA extraction: The total RNA was extracted from samples using SV Total RNA 142 
Isolation System kit according to manufacturer's instructions (Promega). Briefly, the 143 
hippocampal tissue lysates were prepared by adding 1 ml RNA lysis buffer to 342 mg of 144 
tissue weight. The tissue lysates were diluted with SV RNA dilution buffer and RNA was 145 
then adsorbed to a silica membrane-based column where it was purified by a spin 146 
method. RNA was subjected to DNase treatment, washed and eluted with 100 µl of 147 
Nuclease-free water. The RNA purity was checked by the NanoDrop-1000 148 
spectrophotometer, and the RNA integrity was checked by 1% agarose gel 149 
electrophoresis. 150 
2.2.2. cDNA synthesis: Complementary DNA (cDNA) was synthesised by using the 151 
Superscrpit III first strand synthesis system (Life Technologies, 18080-051) according to 152 
the manufacturer's recommendation. Starting from 1µg of total RNA, cDNA was 153 
synthesised by using 50 µM of oligo (dT)20 primer, 40 U of RNaseOUT and 200 U of 154 
Superscrpit III reverse transcriptase enzyme. The cDNA was then purified by using 155 
QIAquick PCR purification kit (Qiagen, 28104) and quantified with the NanoDrop-1000 156 
spectrophotometer. 157 
2.2.3. qRT-PCR: The mRNA expression of GABAB1 and GABAB2 subunits was 158 
investigated by qRT-PCR in 26 TLE-HS and 11 TLE-STG specimens (Table 1) and 10 159 
post-mortem samples (Table 2). The qRT-PCR was performed on a StepOnePlus™ Real-160 
Time PCR System (Applied Biosystems) using TaqMan gene expression assays (Table 161 
3).  A 10 µl volume of PCR reaction mix was prepared by combining template cDNA 162 
sample, TaqMan Universal PCR Master Mix (Applied Biosystems, 4352042) and TaqMan 163 
gene expression assays (Life Technologies). Cyclophilin A (PPIA) and cyclin-dependent 164 
kinase inhibitor 1B (CDKN1B) were selected as reference genes for our study as they 165 
were among the most stably expressed genes in TLE (Wierschke et al. 2010). Results 166 
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were analysed using the 2–∆Ct method and presented as relative gene expression 167 
normalised to the average threshold cycle of the two housekeeping genes.  168 
2.3 Quantitative two colour Western blot (qWB) 169 
2.3.1. Protein extraction and quantification: The hippocampi tissues were 170 
homogenised at 4°C in CelLyticTM (C3228, Sigma) and protease inhibitor cocktail (P8340, 171 
Sigma). The lysate was centrifuged twice at 500 XG for 15 minutes at 4°C. The 172 
supernatant was centrifuged at 20000 XG for 40 minutes at 4°C and pellet was 173 
suspended in 50mM TrisHCl buffer pH 7.5 (TBS). The total protein was then quantified by 174 
Bicinchoninic acid protein assay kit according to the manufacturer's protocol (BCA1, 175 
B9643, Sigma-Aldrich). 176 
2.3.2. Quantitative WB:  The GABAB receptor subunits were investigated by qWB in 9 177 
TLE-HS, 6 TLE-STG, and 4 PMC samples (according to sample availability). 20 µg of 178 
protein was loaded on 8% sodium dodecyl sulphate-polyacrylamide gel for 179 
electrophoresis (SDS-PAGE). The separated proteins were electro-transferred onto a 180 
nitrocellulose membrane, which was washed briefly in phosphate buffered saline (PBS) 181 
for few minutes. The membranes were then blocked with 5% w/v non-fat dry milk (NFDM) 182 
in PBS and 0.1% Tween 20 (PBST) for 1 hour at room temperature (RT). Then they were 183 
incubated with primary diluted antibodies (Table 4) over night at 4°C with gentle shaking. 184 
A generous amount of 0.1% PBST buffer was used to wash the membranes 4 times for 5 185 
minutes each. Then membranes were incubated with infrared-labelled secondary 186 
antibodies for 1 hour at RT followed by 4 washes with 1X PBS for 5 minutes each. The 187 
membranes were scanned on an Odyssey infrared imaging system (LI-COR, 188 
Biosciences, NE, U.S.A.). The 700nm and 800nm channel scanning intensities were set 189 
to 4 and 6 respectively. The images acquired were quantified on the Odyssey software 190 
(version 1.2) according to the software manual and Picariello et al. (2006). GABAB1(a-b), 191 
and GABAB2 bands intensities were normalized to β-actin to eliminate any loading 192 
variation.  193 
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2.4 Immunohistochemistry (IHC)  194 
2.4.1. Brain sections preparation: Sections (10 µm) of paraffin-embedded human 195 
hippocampal tissue were cut by a microtome, mounted onto charged microscope slides 196 
(BDH Superfrost Plus) and stored with desiccant in plastic slide boxes at RT until 197 
required. 198 
2.4.2. Tissue pre-treatment and application of antibodies 199 
The immunohistochemistry antibodies sub-types specificity to human GABAB1a, GABAB1b 200 
or GABAB2 was previously tested (Calver et al. 2000). Immunohistochemistry (IHC) was 201 
conducted on 7 TLE-HS (Table 1) and 5 PMC specimens (Table 2) according to 202 
specimen availability. Following antigen retrieval, sections were rinsed in PBS, 203 
endogenous peroxidase activity blocked by incubation with hydrogen peroxide (0.3% in 204 
PBS) for 30 minutes, and followed by a rinse in fresh PBS. Sections were then incubated 205 
with normal goat serum (NGS) (1:10 in PBS) for 75 minutes, and subsequently overnight 206 
at 4°C with the primary antibodies (Table 4) respectively in PBS containing 1% NGS. 207 
Following incubation with primary antibodies, the sections were washed with fresh PBS 208 
for 1 hour then incubated with secondary biotinylated antibodies (Table 4) for 75 minutes, 209 
rinsed for 1 hour in PBS and incubated with the avidin-biotin peroxidase complex (ABC; 210 
Vector) for 75 minutes. Peroxidase staining was performed by incubating the sections in 211 
0.002% 3.3'diaminobenzidine and 0.002% H2O2 in 50mM Tris buffer, pH 7.6. The sections 212 
were dehydrated, and cover-slipped with diethyl-pyro carbonate (DPX). 213 
2.4.3. Microscope visualization and quantitative IHC (qIHC) 214 
Neuronal counting was performed as before using a stereological method as previously 215 
described (Princivalle et al. 2002; 2003). The number and intensity of GABAB receptor 216 
subunits were quantified in pyramidal and granular cells in TLE-HS and PMC IHC 217 
sections using the Q-Capture Pro 7™ (QCapture 10, 2010) connected to an Olympus 218 
BX60 microscope.  219 
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In order to quantify the immunosignals of the GABAB1 receptor isoforms and subunit, 13 220 
sections from TLE patients and 5 from PMC were analysed. The microscope amplification 221 
used for quantification of each slide was 10 (ocular lens) x 20 (objective lens), giving a 222 
total amplification of 200x. For each slide 6 images of the area of interest (hippocampus) 223 
were captured. The raw relative optical density (ROD) of GABAB immunosignals was 224 
determined using the measuring tools of Q-Capture Pro 7™ software. The pyramidal cells 225 
were marked with a yellow triangle and granular cells with a blue square measuring tool. 226 
The ROD was normalized by subtracting the background (calculated by averaging 10 227 
background spots in each slide). To correct for neuronal loss, ROD per neuron was 228 
calculated by dividing the total ROD on the number of GABAB immunopositive neurons 229 
and excluding glial cells. 230 
 231 
2.4.4. Statistical analysis 232 
The GraphPad Prism 6 software for Windows, version 6.05 was used for the statistical 233 
analysis (San Diego, CA, USA; www.graphpad.com). The Shapiro-Wilk W test was 234 
performed to test the normality of the data. The simple linear regression was used to do 235 
the correlation analysis. The Kruskal-Wallis with Conover-Inman post hoc analysis test 236 
was used, for any experiment, to identify significant differences between samples (* P ≤ 237 
0.05, ** P < 0.01, *** P< 0.001). Data presented as median and interquartile range values. 238 
 239 
3. RESULTS 240 
In this study we have investigated the expression of GABAB receptor subunit transcripts 241 
and proteins in human samples of TLE-HS, TLE-STG, and PMC. The median age of TLE-242 
HS patients was 38 years (range 22-63). Patients had had epilepsy for a median of 23 243 
years prior to surgery (range 2-53).  Patients were taking a median of 3 antiepileptic drugs 244 
at the time of surgery. The patients had simple or complex partial seizures and 36% of 245 
them had also generalized tonic clonic seizures. 26% of patients had a history of febrile 246 
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seizures. Only 14 from 23 patients (60%) of patients were seizure free after 1 year of 247 
epileptic surgery.  248 
 249 
3.1. qRT-PCR 250 
The correlation between PMC mRNA samples versus age and post-mortem interval in 251 
demonstrates no correlation between the mRNA findings and these factors that could 252 
have influence the mRNA expression (supplementary material). The data from qRT-PCR, 253 
obtained from the whole resected hippocampi, show a very similar trend for both GABAB1 254 
and GABAB2 subunits. The comparison of TLE-HS and the PMC samples reveals no 255 
difference in GABAB1 subunit expression between the groups, but possibly an increased 256 
GABAB2 expression in the TLE-HS tissue. In contrast, the comparison of TLE-HS with the 257 
TLE-STG samples showed a statistically significant lower level of expression of GABAB2 258 
in the TLE-HS tissue (see Figure 1).  259 
 260 
3.2. Qualitative and Quantitative WB 261 
Figure 2A shows a double-labelled Western blot image demonstrate a fairly consistent 262 
level of β-actin expression in the three study groups. However, there is a clear gradient of 263 
the expression of all three GABAB variants across the study groups. These proteins are 264 
expressed most strongly in TLE-STG, less strongly in TLE-HS and least strongly in PMC 265 
tissue. The data obtained by quantitative double-labelled analysis (Figure 2B) follows the 266 
same trend although differences between the TLE-HS and the TLE-STG comparisons 267 
were only significant for GABAB2. Comparing TLE-HS to PMC, statistically significant up 268 
regulation differences was are observed for GABAB1a, GABAB1b, and GABAB2. 269 
3.3. Distribution and comparison of GABAB receptor protein immunoreactivity in 270 
PMC and TLE-HS hippocampi 271 
GABAB1a, GABAB1b and GABAB2 receptor proteins appeared to have a similar location in 272 
the TLE-HS and PMC hippocampal sections; furthermore, no evidence of single subunit 273 
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labelling was observed in the hippocampal subregions of either sample category (Figure 274 
3A-F). In PMC cases GABAB2 and GABAB1b exhibited the highest and the lowest 275 
immunoexpression respectively. All the three proteins displayed the highest expression in 276 
the dentate gyrus (DG) followed by the different cornu ammonis (CA) areas (all with 277 
comparable immunointensity), and the subiculum, which showed the lowest level of 278 
immunopositivity.  279 
Figure 4A shows the total number of pyramidal and granular cells per mm3 highlighting 280 
neuronal loss in the TLE-HS. 5B and 5C show the percentage of GABAB positive 281 
pyramidal and granular neurons respectively. Whereas immunopositivity to GABAB1 was 282 
greater in pyramidal PMC than TLE-HS cells it was lower in granular PMC than TLE-HS 283 
cells. In contrast, GABAB2 immunopositivity was more marked in TLE-HS than PMC in 284 
both types of neurons. Figures 4D and 4E show semi-quantitative immunosignal 285 
measurements demonstrating the intensity of immunopositivity per remaining neuron in 286 
PMC and TLE-HS. The GABAB2 signal intensity is higher while GABAB1a is lower in TLE-287 
HS patients compared to PMC in both pyramidal and granular cells. The comparison of 288 
GABAB1b intensity between TLE-HS and PMC cells on the other hand showed higher 289 
GABAB1b intensity in granular and lower intensity in pyramidal cells (resulting not only 290 
from the image shown but from the averaged analysis of 5 patients); however, these 291 
differences did not achieve significance in the small number of samples available for 292 
comparison. 293 
Figure 5 and 6 show how representative pyramidal cells in CA areas and DG granular 294 
neurones reacted with the three antibodies for GABAB1a, GABAB1b and GABAB2 at higher 295 
magnification. The immunosignal proved to be specific for all three antibodies. The left 296 
panel in Figure 5 represents pyramidal neurones in of CA1. The immunoreactivity was 297 
mainly expressed by the cell bodies and apical dendrites; there was no nuclear staining at 298 
all, either in PMC or in the TLE-HS sections. The main difference between PMC and TLE-299 
HS CA1 was the intensity of immunoreactivity in most of the neuronal cells. GABAB1a and 300 
GABAB2 immunoreactivity appeared stronger in a few neurones, whilst the GABAB1b 301 
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immunosignal seemed fainter in the majority of TLE-HS compared to PMC neurons. 302 
Figure 5, right panel shows CA2 pyramidal neurones. The immunosignal, for all three 303 
antibodies, was confined to the cell bodies and apical dendrites in the control specimen. 304 
In the TLE-HS hippocampi there was neuronal loss. Furthermore the remaining neurones 305 
appeared smaller and contracted and the immunosignal seemed stronger in the 306 
cytoplasmic membrane. Figure 6, left panel displays pyramidal neurones in CA3. 307 
Immunopositivity was mainly confined to the neuronal bodies with almost no apical 308 
dendrites being immunolabelled with any of three antibodies in the PMC hippocampus. In 309 
TLE-HS neuronal loss was evident, the cells appeared to be smaller, and the 310 
immunoreactivity was present on the cytoplasmic membrane. There was also an apparent 311 
proliferation of glial cells as reported in literature (Charles et al. 2003; Kim et al. 1990; de 312 
Lanerolle 2012). The right panel of Figure 6 exhibits DG granular cells at higher 313 
magnification. In the PMC specimen the immunoreactivity with all three antibodies was 314 
present exclusively in the cell somata. In TLE-HS sections neuronal loss was evident, in 315 
addition the granule cells were smaller and more dispersed, and immunolabelling was 316 
more intense.  317 
Most of the pyramidal neurons in CAs areas and granule cells in DG were 318 
immunopositive. In addition, supported by recent evidence (Huyghe et al. 2014), some 319 
interneurons and possibly some astrocytes appeared immunopositive to the GABAB 320 
antibodies. It would be appropriate in future to perform double fluorescent immunostaining 321 
to verify which subpopulation of neurons and glia express GABAB receptors. 322 
 323 
4. DISCUSSION 324 
Previous studies have indicated that changes in the GABAB receptors subunits could be 325 
implicated in the pathophysiology of pharmaco-resistant TLE associated with HS (Billinton 326 
et al. 2001; Fürtinger et al. 2003b; Princivalle et al. 2003). Therefore, studying GABAB 327 
receptor protein expression may provide an important contribution to our understanding of 328 
one of the most important mechanisms implicated in temporal lobe epilepsy. 329 
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 330 
The qRT-PCR results obtained in this study showed that there is no major difference in 331 
GABAB expression between TLE-HS and PMC samples. This is in agreement with 332 
previous data (Billinton et al. 2001). In contrast, the TLE-STG samples demonstrated a 333 
higher expression of both subunits compared to TLE-HS and PMC samples. The 334 
quantitative Western blot perfectly mirrored the trend of PCR data for GABAB2, but not for 335 
GABAB1. Figure 1 and 2 clearly demonstrate that the GABAB2 subunit expression is 336 
significantly lower in TLE-HS samples compared to the bioptic TLE-STG, and higher 337 
compared to the PMC as well as the IHC shows. It is difficult to compare qRT-PCR 338 
GABAB2 mRNA to previous in situ hybridization data (Princivalle et al. 2003; Fürtinger et 339 
al. 2003b). However, overall both techniques indicate a higher expression of GABAB2 340 
mRNAs in the epileptic hippocampi compared to the PMC control.  341 
The protein quantification obtained from qWB demonstrated that GABAB1 and GABAB2 342 
expression mirror the mRNA level in TLE-HS and TLE-STG. Visual comparison of the 343 
three proteins by IHC between PMC control and TLE-HS patients displayed a wide 344 
distribution of GABAB isoforms and subunits in both types of specimen. However, as 345 
previously reported (Princivalle et al. 2003; Fürtinger et al. 2003b), the quantitative 346 
comparison showed that, despite neuronal loss in TLE-HS hippocampal samples, there 347 
was an increment of GABAB1b and GABAB2 protein expression per remaining neuron in 348 
the CA areas and DG, compared to the PMC samples.  349 
It may be argued that our findings are contradictory because the quantification of Western 350 
blot and IHC showed opposite trend for GABAB1a. However, it is important to point out that 351 
WB data represents the total GABAB1a expression as we used homogenates of 352 
hippocampal tissue containing neurones, microglia and astrocytes rather than just the 353 
neuronal portion. In contrast, the quantitative IHC data represent GABAB1a expression per 354 
neurone. Comparing the mRNA and protein expression in Figures 1 and 2, it is evident 355 
that the trend of the receptor subunits is the same, demonstrating that GABAB2 356 
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expression is very much lower in the hippocampi of pharmaco-resistant patients 357 
compared to TLE-STG. Previous binding and present immunohistochemical data in 358 
human hippocampal PMC control and epileptic specimens appear in reasonable 359 
agreement (Princivalle et al. 2002).  360 
In the IHC the higher expression of GABAB1b and GABAB2 in the surviving neurones of the 361 
DG reflects the mRNA per neurone levels reported elsewhere (Princivalle et al. 2003; 362 
Furtinger et al. 2003b). In addition, the GABAB receptor autoradiography binding assays, 363 
corrected for neuronal loss (Billinton et al. 2000; Princivalle et al. 2002), showed a 364 
significant increase in receptor density per neurone in specific hippocampal subregions of 365 
the TLE-HS compared to PMC samples. 366 
The lower expression of both GABAB receptor subunits in TLE-HS compared to TLE-367 
STG, could indicate a decline in GABAB receptors which would provide an explanation for 368 
the compromised GABAB functionality previously reported in pharmacological and 369 
electrophysiological studies in animal model and in human TLE (Billinton et al. 2000; 370 
Princivalle et al. 2002; Fürtinger et al. 2003b; Mareš and Kubová 2015; Leung et al. 2016; 371 
Rocha et al. 2015). This may be affecting the formation of fully functional GABAB 372 
receptors: since the heterodimerisation of GABAB1 and GABAB2 in 1:1 stoichiometry is 373 
essential for receptor trafficking and G-protein activation, the GABAB2 subunit could be a 374 
potential target for the development of new agonists or activating transcription factors 375 
drugs, which may have a major clinical impact on the treatment of pharmaco-resistant 376 
TLE-HS patients. However, there are other factors which could explain the reduced 377 
GABAergic inhibition (Gill et al. 2010; Armstrong et al. 2016), and there is a strong 378 
possibility of co-causation. 379 
 380 
The findings of this study could be interpreted in two different ways: GABAB protein 381 
expression in epileptogenic hippocampal tissue could be down-regulated (because of the 382 
higher expression in TLE-STG tissue) or it could be up-regulated (because of the lower 383 
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expression in PMC tissue). The decision which explanation is more likely depends on the 384 
relative merits of the two non-epileptogenic “control”-tissues. Unfortunately, neither PMC 385 
nor non-spiking TLE-STG is a perfect match for the TLE-HS samples of interest for the 386 
kind of experiments conducted here. However, there is no real alternative in human 387 
studies and it is not the first time that neocortex (STG) has been used in studies on TLE 388 
(Teichgrӓber et al. 2009; Rocha et al. 2015). Even human non-epileptogenic hippocampi 389 
removed for other reasons (such as temporal lobe tumours) cannot be considered an 390 
ideal control tissue for TLE-HS samples (Kovács et al. 2012). Son et al. (2015) 391 
demonstrated that tissue surrounding or adjacent to a tumour is physiologically and 392 
molecularly perturbed by the tumour itself or by previous irradiation. 393 
In view of these difficulties, many studies investigating TLE pathophysiology have recently 394 
compared their results obtained in epileptogenic TLE specimens to other surgically 395 
resected samples such as neocortex. The strength of this approach includes the fact that 396 
both sample types contain the same DNA (reducing the risk of intersubjective variability 397 
caused by gene-gene or gene-environment interactions) and that both samples were 398 
obtained and processed in the same way. This approach also avoids the difficulties 399 
associated with comparing TLE-HS tissue removed during epilepsy surgery with PMC-HS 400 
tissue possibly affected by an agonal state and post-mortem changes (Preece et al. 2003; 401 
Tomita 2004; Teichgrӓber et al., 2009; Rocha et al. 2015).  402 
In this study, the expression of mature GABAB receptor proteins was investigated for the 403 
first time in TLE-HS, and in both types of potential “control” tissues, surgically resected 404 
non-spiking TLE-STG and PMC specimens.  405 
 406 
CONCLUSIONS 407 
In agreement with older studies, we found a statistically significant increase in overall 408 
expression of GABAB receptor protein in TLE-HS versus PMC. This finding suggests that 409 
the previously reported reduction in slow IPSPs in TLE-HS cannot be explained by a 410 
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decreased protein expression of the GABAB receptor subunit. Instead this 411 
neurophysiological observation could be due to other causes including post-translational 412 
modification of the GABAB protein. On the other hand, this study shows a statistically 413 
significant lower expression of GABAB2 in TLE-HS samples than in non-epileptogenic 414 
TLE-STG from the same patients. Considering that the PMC values were affected by 415 
agonal or post-mortem changes (or due to undetected differences in clinical or 416 
demographic factors between TLE-HS and PMC subjects) the TLE-STG samples may 417 
represent a more appropriate “control” tissue. Therefore, the downregulation of GABAB2 418 
transcription
 
and GABAB2 mature protein subunit in TLE-HS could represent one of the 419 
reasons for the impaired GABAergic inhibition reported in epileptogenic hippocampal 420 
tissue in the literature.  421 
 422 
LIST OF ABBREVIATIONS 423 
CA   cornu ammonis 424 
GABA   γ-aminobutyric acid 425 
GABAB  γ-aminobutyric acid receptor B 426 
DG   dentate gyrus 427 
HS   hippocampal sclerosis 428 
IHC   immunohistochemistry 429 
IR   immunoreactivity 430 
PMC   post-mortem control 431 
PMI   post-mortem interval 432 
TLE   temporal lobe epilepsy 433 
DG   dentate gyrus 434 
ROD   relative optical density 435 
STG   superior temporal gyrus 436 
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This paper is dedicated to the memory of Professor Norman G. Bowery (1944-2016) 438 
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FIGURE LEGENDS 651 
Figure 1 Quantitative real time PCR of GABAB mRNA receptor subunits. 652 
qRT-PCR mRNA expression of GABAB1 and GABAB2 in 26 TLE-HS, 11 TLE-STG and 10 653 
PM control using TaqMan gene expression Assays and Comparative delta Ct analysis (2-654 
∆CT) method. Statistical analysis: Kruskal-Wallis with Conover-Inman post hoc analysis 655 
test was used to identify significant differences between (* P ≤ 0.05, ** P < 0.01, *** P< 656 
0.001). Data presented as median and interquartile range values. 657 
 658 
Figure 2 Qualitative and quantitative Western blot 659 
(A) Qualitative WB of GABAB1a, GABAB1b, GABAB2 and β-Actin, revealed by double 660 
labelling with IRDye 680 and IRDye 800 secondary antibodies. (B) Quantitative 661 
expression of GABAB1a, GABAB1b and GABAB2 relative to β-Actin. Bands quantification 662 
was done on Odyssey infrared imaging system and Image Studio lite 4.0 software. 663 
Statistical analysis: Kruskal-Wallis with Conover-Inman post hoc analysis test was used to 664 
identify significant differences between (* P ≤ 0.05, ** P < 0.01, *** P< 0.001). Data 665 
presented as median and interquartile range values. 666 
 667 
Figure 3 Qualitative immunohistochemistry 668 
Distribution of GABAB1a, GABAB1b and GABAB2 in PMC and TLE-HS hippocampi. 669 
Photomicrographs show GABAB1a (A, D), GABAB1b (B, E) and GABAB2 (C, F) IR in three 670 
adjacent sections from a post-mortem control and TLE-HS specimen. GABAB2 show the 671 
highest immunosignal, GABAB1a demonstrated a lower immunoreactivity and GABAB1b 672 
displays the lowest immunopositivity. Scale bars represent 4mm in A, B, C and 8 mm in 673 
D, E, F (magnification 5X). 674 
 675 
Figure 4 Quantitative immunohistochemistry 676 
(A) Neuronal densities obtained by adjacent section of both TLE-HS (n=6-11) and PMC 677 
(n=5) stained with Cresyl Violet/Luxol Fast blue and. (B, C) graphs illustrate the 678 
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percentage of GABAB positive pyramidal and granular neurons respectively compared to 679 
PMC. (D, E) graphs show semi-quantitative expression in pyramidal and granular cells of 680 
GABAB subunits in 6 TLE-HS and 2 PMC. Semi-quantitative analysis obtained is 681 
expression of GABA subunits in ROD per neurones. Statistical analysis: Kruskal-Wallis 682 
with Conover-Inman post hoc analysis test was used to identify significant differences 683 
between (* P ≤ 0.05, ** P < 0.01, *** P< 0.001). Data presented as median and 684 
interquartile range values. 685 
 686 
Figure 5 Brightfield photomicrograph displaying immunoreactivity in PMC and TLE-687 
HS CA1 and CA2 688 
Photomicrographs showing the distribution of GABAB1a, GABAB1b, and GABAB2 in human 689 
PMC and TLE-HS patients in the pyramidal cells of the CA1 (panel A); CA2 (panel B); red 690 
harrows show glial cells. Scale bars: 120 µm.  691 
 692 
Figure 6 Brightfield photomicrograph displaying immunoreactivity in PMC and TLE-693 
HS CA3 and DG 694 
Photomicrographs showing the distribution of GABAB1a, GABAB1b, and GABAB2 in human 695 
PMC and TLE-HS patients in the pyramidal cells of the CA3 (panel A); DG (panel B); red 696 
harrows show glial cells. Scale bars: 120 µm.  697 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Table 1: Patient clinical data 
Patients Gender 
age at 
sugery 
(yrs) 
Samples age at onset 
epilepsy 
History of febrile 
seizures Seizures type Current AED 
ILAE surgery 
outcome * Method 
Pt. 01 F 36 TLE-HS 4 Yes Simple or complex partial/ Secondary generalised tonic clonic PHT, VPA NA RT-PCR 
Pt. 02 M 42 TLE-HS 2 Yes Simple or complex partial/ Secondary generalised tonic clonic CBZ,  LCS 1 RT-PCR 
Pt. 03 M 54 TLE-HS NA NA Simple or complex partial CBZ,  LCS, PHT 2 RT-PCR 
Pt. 04 F 24 TLE-HS 1 NA Simple or complex partial/ Secondary generalised tonic clonic LCS, LEV 2 RT-PCR 
Pt. 05 F 45 TLE-HS 29 No Simple or complex partial/ Secondary generalised tonic clonic None 1 RT-PCR 
Pt. 06 M 33 TLE-HS 9 NA Simple or complex partial None 1 RT-PCR 
Pt. 07 M 33 TLE-HS 2 No Simple or complex partial/ Secondary generalised tonic clonic LMT, LEV NA RT-PCR 
Pt. 08 F 22 TLE-HS NA Yes Simple or complex partial/ Secondary generalised tonic clonic LMT, CBZ NA RT-PCR 
Pt. 09 F 39 TLE-HS 2 No Simple or complex partial None NA RT-PCR 
Pt. 10 F 29 TLE-HS 1 Yes Simple or complex partial/ Secondary generalised tonic clonic CBZ, LMT NA RT-PCR 
Pt. 11 M 23 TLE-HS 7 No Simple or complex partial/ Secondary generalised tonic clonic LMT NA RT-PCR 
Pt. 12 F 27 TLE-HS 18 No Simple or complex partial CBZ, LEV 1 RT-PCR 
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Table 1: Patient clinical data (continued) 
Patients Gender 
age at 
sugery 
(yrs) 
Samples age at onset 
epilepsy 
History of febrile 
seizures Seizures type Current AED 
ILAE surgery 
outcome * Method 
Pt. 13 M 31 TLE-HS 11 No Simple or complex partial LEV, CBZ NA RT-PCR 
Pt. 14 M 48 TLE-HS 7 Yes Simple or complex partial None 1 RT-PCR 
Pt. 15 M 48 TLE-HS NA NA NA VPA, LEV NA RT-PCR 
Pt. 16 F 44 TLE-HS NA NA Simple or complex partial PGB, VPA NA RT-PCR 
Pt. 17 M 63 TLE-HS 17 Yes Simple or complex partial LEV,CLB 1 RT-PCR 
Pt. 18 M 38 TLE-HS NA NA Simple or complex partial/ Secondary generalised tonic clonic 
LMT, CBZ, 
GBP 5 RT-PCR /WB 
Pt. 19 M 25 TLE-HS 2 Yes Simple or complex partial/ Secondary generalised tonic clonic ZNS, TPM 1 RT-PCR/ WB 
Pt. 20 M 30 TLE-HS 28 No Simple or complex partial LEV, TMP, LCS NA WB 
Pt. 21 M 44 TLE-HS 6 Yes Simple or complex partial CLB,CBZ,TPM NA IHC 
Pt. 22 F 38 TLE-HS NA NA Simple or complex partial NA NA IHC 
Pt. 23 M 30 TLE-HS 19 No Simple or complex partial/ Secondary generalised tonic clonic 
CBZ , PGB, 
CLB NA IHC 
Pt. 24 M 27 TLE-HS 15 Yes Simple or complex partial LMT, VPA NA IHC 
Pt. 25 F 24 TLE-HS 12 Yes Simple or complex partial LEV, PGB NA IHC 
Pt. 26 F 40 TLE-HS NA NA NA NA NA IHC 
Pt. 27 F 39 TLE-HS 22 No Simple or complex partial/ Secondary generalised tonic clonic 
LMT, CBZ, 
TPM NA IHC 
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Table 1: Patient clinical data (continued) 
Patients Gender 
age at 
sugery 
(yrs) 
Samples age at onset 
epilepsy 
History of febrile 
seizures Seizures type Current AED 
ILAE surgery 
outcome * Method 
Pt. 28 M 42 TLE-HS/TLE-STG NA Yes Simple or complex partial CBZ,  LCS, CLB 4 RT-PCR 
Pt. 29 F 32 TLE-HS/TLE-STG 19 No Simple or complex partial/ Secondary generalised tonic clonic 
LMT, CBZ, 
GBP 4 RT-PCR 
Pt. 30 F 54 TLE-HS/TLE-STG 1 Yes Simple or complex partial LMT,PGB 1 RT-PCR 
Pt. 31 M 41 TLE-HS/TLE-STG 12 No Simple or complex partial CBZ , LMT 1 RT-PCR 
Pt. 32 M 61 TLE-HS/TLE-STG NA NA Simple or complex partial LMT, CBZ, GBP 3 WB 
Pt. 33 F 31 TLE-HS/TLE-STG 29 NA Simple or complex partial PB 1 WB 
Pt. 34 M 35 TLE-HS/TLE-STG 17 No Simple or complex partial/ Secondary generalised tonic clonic CBZ, LEV 1 WB 
Pt. 35 F 44 TLE-HS/TLE-STG 16 Yes Simple or complex partial TPM 1 RT-PCR 
Pt. 36 F 34 TLE-HS/TLE-STG 0.5 NA Secondary generalised tonic clonic LMT, LEV 1 RT-PCR 
Pt. 37 M 51 TLE-HS/TLE-STG 45 No Simple or complex partial NA NA RT-PCR 
Pt. 38 F 22 TLE-HS/TLE-STG 9 No Simple or complex partial/ Secondary generalised tonic clonic 
LCS, LMT, 
TPM, PB 5 RT-PCR 
Pt. 39 M 48 TLE-HS/TLE-STG 1 No Simple or complex partial CBZ, PER 4 RT-PCR/WB 
Pt. 40 F 51 TLE-HS/TLE-STG 40 Yes Simple or complex partial/ Secondary generalised tonic clonic LCS, LEV 1 RT-PCR/WB 
Pt. 41 F 25 TLE-HS/TLE-STG 19 No Simple or complex partial/Secondary generalised tonic clonic LEV, PB, LCS 4 RT-PCR/WB 
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Table 1 reports the relevant clinical data of patients used in this study. Samples: Patients (1-27) sclerotic hippocampi from Temporal lobe 
epilepsy patients (TLE-HS). Patients (28-41): Superior temporal gyrus (STG) from TLE-HS patients. Antiepileptic drugs (AEDs): CBZ, 
Carbamazepine; CLB, Clobazam; CNP, Clonazepam; GB, Vigabatrin; LCS, Lacosamide; LEV, Levetiracetam; LMT,Lamotrigine; OXC, 
Oxcabazepine; PB, Phenobarbital; PER: Perampanel; PGB, Pregabalin, PHT, Phenytoin; TPM, Topiramate; VPA, Valproate. (NA): not 
available. * ILAE Classification of Surgical outcome: 1) completely seizure free, No auras; 2) only auras,no other seizures; 3) 1-3 seizure 
days per year, ± auras; 4) 4 seizure days per year to 50% reduction of baseline seizure days, ± auras; 5) less than  50% reduction of baseline 
seizure days, ± auras. Methods: quantitative real-time polymerase chain reaction (qRT-PCR), quantitative Western blot (qWB) and 
Immunohistochemistry (IHC), not available (NA). 
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Table 2: Post-mortem samples: 
Sample Gender  Age (yrs) PMI (hrs) 
PMC 01 M 71 38.5 
PMC 02 M 38 80.35 
PMC 03 M 63 42 
PMC 04 M 43 15 
PMC 05 F 53 29.5 
PMC 06 F 78 23.3 
PMC 07 F 80 49.1 
PMC 08 M 85 51.3 
PMC 09 F 78 51.3 
PMC 10 F 64 79 
PMC 11 M 91 48 
PMC 12 F 83 20 
PMC 13 F 88 49.25 
 
Table 2 shows post-mortem samples' features 
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qRT-PCR
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Western Blot
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Gene 
Symbol Name cellular function Task TaqMan assay ID
amplicons' 
length bp R
2 Efficiency
GABBR
1 (a,b)
gamma-
aminobutyric acid 
(GABA) B receptor, 
1
synaptic 
transmission, 
GABA signalling 
pathway
Target 
gene Hs00559488_m1 68 0.95 98.03
GABBR
2
gamma-
aminobutyric acid 
(GABA) B receptor, 
2
synaptic 
transmission, 
GABA signalling 
pathway
Target 
gene Hs01554998_m1 158 0.98 96.45
PPIA peptidylprolyl isomerase A
protein metabolism
and folding
reference 
gene Hs04194521_s1 97 0.97 96.84
CDKN1
B
cyclin-dependent 
kinase inhibitor 1B 
(p27, Kip1)
cell growth and 
division
reference 
gene Hs01597588_m1 151 0.97 99.66
Table 3: TaqMan gene expression assays
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Quantitative western blot
Proteins Primary antibody
Primary 
antibody 
dilution
Secondary antibody
secondary 
antibody 
dilution
GABBR1 
(a,b)
Rabbit GABBR1
1:500
IRDye® 800CW goat anti-
rabbit IgG
(926-32211,LI-COR®
Bioscience)
1:5000(Cell Signaling
Technology®, S3835)
GABBR2
Rabbit GABBR2
1:500
IRDye® 800CW goat anti-
rabbit IgG
(926-32211,LI-COR®
Bioscience)
1:5000(ab75838, abcam®)
β-actin Mouse β-actin 1:1000
IRDye® 680LT goat anti-
mouse IgG
(926-68020, LI-COR®
Bioscience)
1:10000
IHC
Proteins Primary antibody
and sequence
Primary 
antibody 
dilution
Secondary antibody
secondary 
antibody 
dilution
GABBR1a
Rabbit polyclonal 
GABBR11a
NH2-
CHPPWEGGIRYRGLTRD
QVK-COOH residues 33-
51
1:500 biotinylated goat anti-
rabbit 1:200
GABBR1b
Rabbit polyclonal 
GABBR11b
NH2-
HSPHLPRPHPRVPPHPS
-COOH residues 30
¯
47
1:500 biotinylated goat anti-
rabbit 1:200
GABBR2
α glutathione S-
transferase (GST) fusion 
protein was generated 
against the intracellular C-
terminus
amino acids 745–941
1:100 biotinylated goat anti-
rabbit 1:200
All antibodies were diluted with 0.1% PBST buffer.
Table 4. Antibodies and their concentration used for WB & IHC
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HIGHLIGHTS 
• This study investigates GABAB in three types of human specimens: two types from patients 
with temporal lobe epilepsy with sclerotic hippocampal samples (TLE-HS), non-spiking 
ipsilateral superior temporal gyrus (TLE-STG) and third is hippocampal tissue from (post-
mortem controls (PMC).  
• This study investigates GABAB by using three different quantitative techniques: 
RT-PCR, Western blot, and immunohistochemistry in human specimens 
• The higher expression of mature GABAB protein in TLE-HS than PMC is in agreement with 
previous studies 
• On the other hand, this study shows a statistically significant lower expression of GABAB2 in 
TLE-HS samples than in non-epileptogenic 
• Therefore, the downregulation of GABAB2 transcription and GABAB2 mature protein subunit in 
TLE-HS could represent one of the reasons for the impaired GABAergic inhibition reported in 
epileptogenic hippocampal tissue 
 
 
 
